WASHINGTON — Pharmaceutical industry giant GSK plans to depart the biotechnology industry’s largest trade group, the ...

UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over claims that a discontinued version of its heartburn drug Zantac caused cancer.

GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

British pharmaceutical company GSK has agreed to pay $2.3 billion to settle lawsuits alleging that its heart burn medication Zantac caused cancer. GSK has settled 80,000 Zantac lawsuit.

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), following a string of exits by companies including Pfizer, UCB, WuXi AppTec and ...

Shares in British pharmaceutical giant GSK rose after the company said it resolved a vast majority of lawsuits in the U.S. claiming its discontinued heartburn medicine Zantac caused cancer.

GSK shares in London jumped 5% Thursday after the British pharmaceutical giant said it has resolved most of the U.S. lawsuits ...

the London-based pharma giant announced in an Oct. 21 release. Called the Cambridge-GSK Translational Immunology Collaboration (CG-TIC), the partnership will build on GSK and Cambridge’s ...

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...

The market expects GSK (GSK) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook is ...